Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Pulse Biosciences, Inc. (PLSE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets June 30, December 31, 2023 2022 ASSETS Current assets: Cash and cash equivalents $ 58,747 $ 61,139 Prepaid expenses and other current assets 1,211 1,008 Total current assets 59,958 62,147 Property and equipment, net 1,755 1,961 Intangible assets, net 2,218 2,551 Goodwill 2,791 2,791 Right-of-use assets 7,670 8,062 Other assets 365 365 Total assets $ 74,757 $ 77,877 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 1,794 $ 1,573 Accrued expenses 2,844 2,595 Lease liability, current 975 896 Related party note payable, current — 917 Total current liabilities 5,613 5,981 Lease liability, less current 8,644 9,144 Related party note payable, less current — 65,000 Total liabilities 14,257 80,125 Stockholders..."
07/20/2023 8-K Quarterly results
05/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2023 8-K Quarterly results
Docs: "PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets March 31, December 31, 2023 2022 ASSETS Current assets: Cash and cash equivalents $ 54,098 $ 61,139 Prepaid expenses and other current assets 849 1,008 Total current assets 54,947 62,147 Property and equipment, net 1,865 1,961 Intangible assets, net 2,384 2,551 Goodwill 2,791 2,791 Right-of-use assets 7,869 8,062 Other assets 365 365 Total assets $ 70,221 $ 77,877 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 2,160 $ 1,573 Accrued expenses 3,091 2,595 Deferred revenue 4 — Lease liability, current 935 896 Related party note payable, current 801 917 Total current liabilities 6,991 5,981 Lease liability, less current 8,898 9,144 Related party note payable, current 65,000 65,000 Total liabilities 80,8..."
05/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
05/09/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...
05/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment to Employment Agreement, between Kevin Danahy and Pulse Biosciences, Inc.",
"Amendment to Employment Agreement, between Darrin Uecker and Pulse Biosciences, Inc."
05/01/2023 8-K Quarterly results
03/21/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "First Amendment to Loan Agreement, between Pulse Biosciences, Inc. and Robert W. Duggan"
12/06/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
09/23/2022 8-K Amended existing or entered into new employment agreement with an officer
Docs: "LOAN AGREEMENT",
"AMENDMENT TO EMPLOYMENT AGREEMENT",
"Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation"
08/10/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
04/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Pulse Biosciences, Inc. Announces Rights Offering HAYWARD, Calif. [Business Wire] - April 14, 2022 - Pulse Biosciences, Inc. , a novel bioelectric medicine company, today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $0.001 per share as of the close of market on April 25, 2022 . The offering is to commence on or about May 4, 2022."
03/31/2022 8-K Quarterly results
Docs: "Webcast and Conference Call Information Pulse Biosciences’ management will host a conference call today, March 31, 2022, beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers. A live and recorded webcast of the event will be available at https://investors.pulsebiosciences.com/. ® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial..."
03/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer HAYWARD, Calif. [Business Wire] – February 9, 2022. Pulse Biosciences, Inc. , a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ technology, today announced the appointment of Kevin Danahy to the newly created role of Chief Commercial Officer."
02/08/2022 8-K Quarterly results
01/11/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Pulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results HAYWARD, Calif. [Business Wire] – January 11, 2022. Pulse Biosciences, Inc. , a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ technology, today announced preliminary unaudited fourth quarter 2021 financial and operational results."
11/24/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/06/2021 8-K Resignation/termination of a director
Docs: "Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors HAYWARD, Calif. [Business Wire]– Oct. 5, 2021. Pulse Biosciences, Inc. , a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ technology, today announced the appointment of Laureen DeBuono to its Board of Directors. Concurrent to Ms. DeBuono’s appointment, Kenneth Clark has resigned from the Board of Directors."
08/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Pulse Biosciences Announces Appointment of Mitchell E. Levinson as Chief Strategy Officer HAYWARD, Calif. [Business Wire]– August 19, 2021. Pulse Biosciences, Inc. , a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ technology, today announced the appointment of Mitchell E. Levinson to the newly created role of Chief Strategy Officer, effective immediately, in addition to the continuation of his role as a member of the Pulse Biosciences Board of Directors."
08/09/2021 8-K Quarterly results
06/10/2021 8-K Quarterly results
06/09/2021 8-K Quarterly results
05/20/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy